



ISOGENICA- UPCOMING NATURE WEBINAR:
VHH as building blocks for immune and tumour cell-targeting

**VHH as building blocks for
immune and tumour
cell-targeting**

Speaker: Bill Eldridge

Date/Time: 20th October at 4pm BST



**BISPECIFICS &
MULTISPECIFICS**

VHH-only bispecifics offer improved targeting and tissue penetration for solid tumours. VHH can also be combined with conventional antibodies to create novel bispecifics

Tune in to hear Isogenica's CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.

Join to learn more about recent advances in VHH therapeutics and remarkable next generation biotherapeutic pipeline.


Discover:

- What are the potential applications of VHH antibodies?

- What are VHH and their unique characteristics which make them applicable as immune cell recruiting agents.
- VHH-based bi-specifics: what differentiates them from the existing classes of bi-specific antibodies.

REGISTER FOR THE WEBINAR

NEW APPLICATION NOTE: PD-L1 VHH as Functional Antagonists



READ THE APPLICATION NOTE

BIO-EUROPE®

OCT. 25–28, 2021

DIGITAL»»




isogenica

IS ATTENDING

Isogenica is attending BIOEurope! We look forward to speaking to you if you would like to discuss our discovery projects structure or learn more about our VHH pipeline. Contact bd@isogenica.com to schedule a meeting.

PRESS RELEASE: ISOGENICA- PIPEBIO COLLABORATION



Isogenica announced the deployment of the Pipe Bio Bioinformatic Cloud. Such collaborations enable the rapid acceleration of drug discovery efforts.

[READ THE PRESS RELEASE](#)

ABOUT ISOGENICA

Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases.



PARTNER WITH US

Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to successfully build a broad pipeline of programs that are now advancing into pre-clinical and through early clinical development with our partners.

[Find out more >>](#)



[view this email in your browser](#)

Copyright © Isogenica 2021 All rights reserved.



Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).